Butterfly Q2 Margin Climbs to 63%

Butterfly Network (NYSE:BFLY) reported mixed Q2 2025 results, achieving a record GAAP gross margin of 63.7% and narrowing its adjusted EBITDA loss to $6.2 million, while increasing cash reserves to $148.1 million due to operational discipline and a recent capital raise. However, GAAP revenue of $23.4 million slightly missed analyst expectations, prompting management to revise full-year 2025 revenue guidance downward to $91-$95 million, despite an improved full-year adjusted EBITDA loss outlook. This indicates strong operational efficiency gains, but tempered revenue growth expectations, with future focus on product innovation and enterprise contract expansion.

Analysis

Butterfly Network's second-quarter fiscal 2025 results illustrate a company successfully executing on operational efficiency but facing headwinds in top-line growth. The firm achieved a record GAAP gross margin of 63.7%, a significant 5.1 percentage point year-over-year increase, and narrowed its adjusted EBITDA loss to $6.2 million from $8.1 million in the prior year. This financial discipline is further evidenced by a record-low quarterly operational cash use of $7.1 million and a strengthened cash position of $148.1 million. However, these operational gains are overshadowed by a slight GAAP revenue miss ($23.4 million vs. a $23.72 million estimate) and, more critically, a downward revision of full-year revenue guidance to $91-$95 million. This new range implies approximately 13% annual growth, a notable deceleration from the previously targeted 20%. Revenue composition reveals that growth was primarily driven by a 25% increase in product revenue, fueled by international sales of the iQ3 device, while U.S. revenue and, importantly, software and services revenue both remained flat year-over-year. While the company points to a strong pipeline with upcoming launches like the Compass AI platform, a pending major hospital contract, and FDA-cleared AI applications, the current growth trajectory and leadership transition temper the near-term outlook.

Key Decisions for Investors

• Investors should closely monitor the execution of key growth catalysts in the upcoming quarters, particularly the commercial adoption of the Compass AI platform and the finalization of the announced top-five global hospital contract, as these are now critical to offsetting the slower growth implied by revised guidance.
• Given the stagnation in software revenue and flat U.S. sales, it is prudent to scrutinize the revenue mix in future earnings, as a re-acceleration in these high-value segments is necessary to support a long-term growth valuation beyond international hardware sales.
• Consider the current tension between operational discipline and growth investment; while improved margins and lower cash burn are positive, investors should assess whether the company can successfully fund and commercialize its next-generation P5 chip and device platform to reignite growth without compromising its newfound cost controls.